Could a modified atkins diet help fight brain cancer?
NCT ID NCT02286167
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a modified Atkins diet combined with intermittent fasting is possible and has any effect in 25 people with glioblastoma, an aggressive brain cancer. Participants followed the diet for several weeks while researchers checked if they could stick with it and measured changes in brain chemicals. The goal was to see if this diet approach is worth studying further as a supportive therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- modified Atkins-based intermittent fasting diet
- What this could lead to
- If successful, this diet approach could offer a supportive strategy to help manage glioblastoma by altering brain chemistry.
- What could go wrong
- This is a very small, early feasibility study with only 25 participants, so results may not apply widely. The diet is demanding and may be hard to follow long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
25 people
The number who actually took part.
- Started
-
Nov 2014
- Finished
-
Jul 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients must have a clinical and histopathologic diagnosis of GBM, have completed \>80% of prescribed concurrent radiation therapy and adjuvant temozolomide without CTCEA grade 3 or 4 toxicity, and be greater than 7 months from the time of completion of concurrent chemoradiotherapy. 2. Karnofsky performance status \>/= 60. 3. Patients must be at least 18 years of age. 4. Patients must be eligible to undergo a ketogenic or Atkins based diet according to baseline body mass index (BMI, see exclusion criteria), comorbid medical conditions (see exclusion criteria), and baseline laboratory assessment (see exclusion criteria). 5. Patients must be of appropriate mental capacities with sufficient social support so as to be able to complete required study activities (i.e. diet record, etc) and able to provide written informed consent. Exclusion Criteria: 1. Patients with a history of a metabolic disorder including documented defect in urea metabolism (including documented history of gout), carnitine deficiency (primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency), fatty acid metabolism, beta-oxidation defects, pyruvate carboxylase deficiency, mitochondrial function, porphyria, or nephrolithiasis. 2. Severe acute infection. 3. BMI \> 35.0 or BMI \< 20.0. 4. Active bowel obstruction, ileus, or active or remote pancreatitis. 5. Clinically significant heart failure (NYHA \>2), recent myocardial infarction, or symptomatic atrial fibrillation. 6. Clinically significant renal disease (creatinine \>2.0 mg/dL, urea \>100 mg/dL). 7. Clinically significant hepatic dysfunction (alanine or aspartate aminotransferase \>7 times the upper limit of normal). 8. Patients with insulin-dependent diabetes mellitus. 9. Conditions that may increase the risk of the diet or significantly reduce compliance (i.e. cognitive impairment, frank dementia, etc). 10. Other concurrent experimental therapies. 11. Milk allergy. 12. Treatment with the modified Atkins diet (MAD) for any cause within the 9 months prior to study enrollment 13. Patient inability to complete baseline screening 3-day diet record.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma multiforme are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Sugar-Coated proteins on cancer cells
- Off-the-Shelf immune cells target solid tumors
- Could a parasite drug fight childhood brain tumors?
- Can mapping the Blood-Brain barrier in brain tumors unlock new clues?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack